GSK To Co-Promote Advair With Mitsubishi Tanabe Pharma In Japan
This article was originally published in PharmAsia News
Executive Summary
GlaxoSmithKline and Mitsubishi Tanabe Pharma will be co-promoting chronic obstructive pulmonary disease treating Advair Diskus (fluticasone propionate plus salmeterol) staring April. Through the collaboration, GSK aims to increase awareness and provide Japanese patients information on the drug as a treatment option. In Japan, there are 4.5 million COPD patients and 2,500 people die of the disease annually. (Click here for more - Japanese language)